Regarding drug-induced cardiotoxicity in breast cancer patients, a study revealed that GDF-15 can predict the risk of cardiotoxicity in breast cancer patients receiving adjuvant trastuzumab-based anti-HER2 therapy (Putt et al., 2015). This evidence concerns the gene ERBB2 and breast carcinoma.